Methylation of a group of microRNA genes: markers of renal cell carcinoma metastasis

Background. Renal cell carcinoma (RCC) is asymptomatic up to severe stages and is characterized by a high mortality rate, reaching 90 % with the development of a metastatic process.Objective: to determine the group of microRNA genes, the methylation of which is associated with the progression of the...

Full description

Bibliographic Details
Main Authors: N. V. Apanovich, V. I. Loginov, E. A. Filippova, D. S. Khodyrev, A. M. Burdennyy, I. V. Pronina, N. A. Ivanova, S. S. Lukina, T. P. Kazubskaya, V. B. Matveev, A. V. Karpukhin, E. A. Braga
Format: Article
Language:Russian
Published: ABV-press 2021-02-01
Series:Onkourologiâ
Subjects:
Online Access:https://oncourology.abvpress.ru/oncur/article/view/1348
Description
Summary:Background. Renal cell carcinoma (RCC) is asymptomatic up to severe stages and is characterized by a high mortality rate, reaching 90 % with the development of a metastatic process.Objective: to determine the group of microRNA genes, the methylation of which is associated with the progression of the disease, in particular, with metastasis.Materials and methods. Methylation-specific polymerase chain reaction in a representative sample of RCC patients (98 cases) showed an increase in the methylation status of 6 microRNA genes (MIR9-1, MIR9-3, MIR34b/c, MIR130b, MIR1258, MIR107) in tumor DNA samples relative to matched samples of histologically unchanged tissue.Results. For 4 genes (MIR9-1, MIR107, MIR130b, MIR1258), a significant association of methylation with late (III-IV) stages, tumor size, loss of differentiation, and metastasis to lymph nodes or distant organs was shown. These 4 genes were used to compose a potential metastatic prognosis marker system with a clinical sensitivity of 68 % and a specificity of 84 % (area under curve 0.83), which will be applied in the final development of a system for personalized therapy of RCC patients.Conclusion. The association of methylation of the MIR1258 with RCC metastasis has been shown for the first time and is of independent interest as a new promising marker for the prognosis of metastatic relapses.
ISSN:1726-9776
1996-1812